Korea Investment CORP raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,180,901 shares of the company’s stock after purchasing an additional 50,868 shares during the period. Johnson & Johnson accounts for 1.3% of Korea Investment CORP’s portfolio, making the stock its 9th largest position. Korea Investment CORP owned approximately 0.08% of Johnson & Johnson worth $288,511,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. State Street Corp increased its position in shares of Johnson & Johnson by 4.3% during the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after acquiring an additional 6,656,371 shares in the last quarter. Harbour Capital Advisors LLC increased its position in shares of Johnson & Johnson by 13,327.8% during the second quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock valued at $18,909,000 after acquiring an additional 2,482,843 shares in the last quarter. Bank of Nova Scotia increased its position in shares of Johnson & Johnson by 94.5% during the first quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock valued at $145,914,000 after acquiring an additional 569,313 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $65,598,000. Finally, CIBC World Markets Inc. increased its position in shares of Johnson & Johnson by 111.8% during the first quarter. CIBC World Markets Inc. now owns 948,655 shares of the company’s stock valued at $118,155,000 after acquiring an additional 500,662 shares in the last quarter. 66.06% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Korea Investment CORP Acquires 50,868 Shares of Johnson & Johnson (JNJ)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/12/korea-investment-corp-acquires-50868-shares-of-johnson-johnson-jnj.html.

Shares of Johnson & Johnson (NYSE:JNJ) opened at $139.56 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The stock has a market cap of $374,930.72, a price-to-earnings ratio of 19.55, a price-to-earnings-growth ratio of 2.84 and a beta of 0.82. Johnson & Johnson has a fifty-two week low of $109.32 and a fifty-two week high of $144.35.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. Johnson & Johnson’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.68 EPS. equities research analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.41%. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

Several equities research analysts recently issued reports on the stock. UBS AG restated a “buy” rating and issued a $148.00 target price (up previously from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. Goldman Sachs Group, Inc. (The) cut shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and raised their target price for the stock from $125.00 to $130.00 in a report on Wednesday, September 20th. BMO Capital Markets restated a “buy” rating and issued a $145.00 target price on shares of Johnson & Johnson in a report on Friday, September 1st. Alembic Global Advisors cut shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Finally, Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock an “outperform” rating in a report on Thursday, October 19th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $143.70.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.